logo
The S&P 500 fades despite tech rally — plus, the crosscurrents driving Lilly's volatile day

The S&P 500 fades despite tech rally — plus, the crosscurrents driving Lilly's volatile day

CNBC4 days ago
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Market moves : The S & P 500 turned negative Thursday afternoon after shares of major drugmakers came under pressure from President Donald Trump over prescription prices. Trump posted on social media letters that were sent to 17 pharmaceutical companies, including Club names Eli Lilly and Bristol Myers Squibb , asking them to cut U.S. drug prices. The letters mention the executive order the president signed in May that aims to reduce drug prices in the U.S. by comparing them to what's paid in other developed nations. This pricing push is separate from the sector-specific tariffs that Trump has threatened the pharmaceutical industry with. The stock market would look a lot worse if it weren't for the big post-earnings moves in Club names Meta Platforms , up 12%, and Microsoft , up 4%. Microsoft became the second stock to join the $4 trillion club, following fellow portfolio member Nvidia , which did so earlier this summer. But as of this writing, Microsoft was off its session highs and appeared unlikely to close above that market cap threshold. Tariff deadline : The S & P 500 had been rallying for much of the session but was losing steam even before the drug price news. Investors might be dealing with a little bit of a hangover from Wednesday when Federal Reserve Chairman Powell hesitated to pencil in an interest rate cut in September due to caution about whether tariffs will be inflationary. We will also watch out for more trade deals ahead of Friday's Trump administration-imposed "reciprocal" tariff deadline. Treasury Secretary Scott Bessent told CNBC on Thursday morning the U.S. has the "making of a deal" with China. In the afternoon, Trump froze Mexico's tariffs at 25% for 90 days as talks continued. The European Union made a trade deal with the U.S. on Sunday. Other countries reaching deals with Trump included Japan last Thursday and the United Kingdom back on May 8. Diabetes trial : In other Lilly news, the company announced the topline results of its highly anticipated SURPASS-CVOT Phase 3 trial on Thursday. This was a head-to-head trial comparing Mounjaro (tirzepatide) versus Trulicity (dulaglutide). Both drugs are in the GLP-1 class. The goal of the study was to prove that Mounjaro is an acceptable alternative in treating patients with Type 2 diabetes with cardiovascular risk. The results confirmed just that. While some of the more bullish investors were hoping for a more significant superiority, we still view the outcome as a positive step forward. It means Mounjaro's label will potentially expand to include cardiovascular risk reduction, an update that could drive broader insurance coverage. That said, this trial update is not the most important factor on our radar when it comes to Lilly. That event will be next week's earnings — and more specifically, what management says about sales expectations for Mounjaro and sister drug Zepbound in the second half of the year, especially in light of Novo Nordisk's surprise guidance cut earlier this week. While Novo's stumble makes it clear that Eli Lilly is gaining share in the lucrative GPL-1 market, we sold some shares on Tuesday to hedge against the possibility that GLP-1 market growth did not expand as fast as predicted, impacting the company's guidance. Shares of Lilly opened Thursday lower before mounting a comeback, only to rollover into the red after Trump went public with his drug price threats. As of 2:45 p.m. ET, shares of Lilly were down about 2%. At its highs of the day, the stock was up about 0.8%. Up next : Apple and Amazon report after Thursday's close. In addition to those two "Magnificent Seven" stocks, Reddit , Coinbase , Roku , Cloudflare ,and MicroStrategy report earnings. Before Friday's opening bell, we will get earnings from Club name Linde , Exxon Mobil , Chevron , Colgate-Palmolive , Regeneron and Dominion Energy . On the data side, the July nonfarm Payroll report will be out Friday morning. According to FactSet, the economy is expected to have added 115,000 jobs for the month. (See here for a full list of the stocks in Jim Cramer's Charitable Trust.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

South Korea pledges to help companies cope with higher US tariffs
South Korea pledges to help companies cope with higher US tariffs

Yahoo

time17 minutes ago

  • Yahoo

South Korea pledges to help companies cope with higher US tariffs

By Jihoon Lee SEOUL (Reuters) -South Korea will prepare measures to help companies cope with higher U.S. tariffs and expand into new markets, the Finance Ministry said on Tuesday, as it kicked off a task force to prepare the new administration's economic policy plans. On the domestic front, the government will come up with measures to boost short-term demand, as well as financial support for mid- to long-term technology development to enhance market competitiveness, it said in a statement. South Korea reached a trade deal with the U.S. last week, just days before President Donald Trump's threatened 25% tariff rate was due to come in on its exports to the United States. The trade deal set tariffs on exports from the Asian country at 15%, still higher than a baseline 10% rate and the near zero tariffs for exports under a Korea-U.S. free trade agreement. Still, topics left unresolved by the deal provide scope for more disputes as the two countries prepare for a summit between Trump and new South Korean President Lee Jae Myung in the coming weeks. Trump may use the summit to try to squeeze more concessions on areas such as defence costs and corporate investments, left out of the deal, while non-tariff barriers and currency could prove thorny issues, experts said. South Korea's Finance Ministry, however, sought to give a positive spin on the agreement. The deal reduced uncertainty over the trade environment, while a $350 billion investment package included in the deal will provide new business opportunities for companies, deepen economic cooperation between the two countries, and contribute to a more stable supply chain, the ministry said. The administration of President Lee also plans to prepare policy measures to foster new industries, such as artificial intelligence, semiconductors and "K-contents" and include them in economic growth strategies and budget plans due to be announced later this month. K-contents refers to a range of cultural and entertainment goods produced by the country ranging from K-pop to Korean dramas that have boomed globally. The ministry vowed to bring regulatory improvements to vitalise business activity, as it kicked off a meeting with the country's major business groups. Asia's fourth-largest economy grew in the second quarter at the fastest pace in more than a year on rebounding consumer spending and a surge in technology exports, but still faces headwinds from slowing global trade amid the sweeping tariffs. The International Monetary Fund last week raised its outlook for most advanced and emerging economies this year based on developments around U.S. tariff negotiations, but South Korea was among the exceptions, with its 2025 growth forecast revised down to 0.8% from 1.0%.

Trump Has Soured on Putin. Putin Couldn't Care Less.
Trump Has Soured on Putin. Putin Couldn't Care Less.

New York Times

time17 minutes ago

  • New York Times

Trump Has Soured on Putin. Putin Couldn't Care Less.

President Trump has not scared the Russian elite. Last week, he declared himself 'disappointed' with Vladimir Putin and imposed a shorter deadline — expiring this Friday — for an end to the war in Ukraine, threatening severe economic punishment if it was missed. In Moscow, no one took it seriously. After weathering more than three years of sanctions, the Kremlin believes it can handle anything thrown at it — that's if Mr. Trump even follows through, which many in Moscow doubt. But there's a deeper reason for the dismissive response. Mr. Putin has, according to Kremlin insiders I talked to, concluded that negotiating with the United States makes no sense and that compromise is pointless. Hostility, not friendship, is the policy. The imminent visit to Moscow of America's envoy for peace missions, Steve Witkoff, won't change that. Mr. Trump may have soured on Mr. Putin, but Russia's president couldn't care less. Six months ago, things were very different. When Mr. Trump returned to the presidency, many in Moscow hoped that a thaw in U.S.-Russia relations might be possible. Along with friendly public remarks from both presidents and negotiations in Saudi Arabia, there were other encouraging signs of détente. Russian propagandists refrained from criticizing the new American administration or Mr. Trump personally, apparently under orders from the Kremlin. (President Emmanuel Macron of France became the main target of attacks instead.) Soon, American businessmen began showing up in Moscow, calling themselves sponsors of Mr. Trump's campaign. They claimed that sanctions would be lifted and even that the president still dreamed of building a Trump Tower in Moscow. The Russian officials and entrepreneurs I spoke to were wary, but they wanted to believe that peace was possible and that Mr. Trump might persuade Mr. Putin to end the war. It seemed as if the dream of renewed cooperation with America might come true. It quickly became clear that this was wishful thinking. Everyone now realizes that Mr. Putin has no desire to end the war, which remains his main tool for controlling society. Worse, he has lost faith in the very idea of reaching agreements with the United States. According to the people I talked to, his view is that any American administration, by definition, is temporary — and so any deal with it is meaningless. Mr. Trump is in charge today, but in three years he might not be. Personal rapport means nothing. To Mr. Putin, it is no longer possible to build a working relationship with America. Kremlin propagandists sense the honeymoon is coming to an end. They're still avoiding direct attacks on Mr. Trump himself, but they're going after those around him. Senator Lindsey Graham, in particular, has been singled out as a 'Russophobic' extremist, especially after he suggested that Mr. Putin should 'call the Ayatollah' to ask what would happen on Day 51 after Mr. Trump's first ultimatum. On a recent episode of the flagship political talk show on the state-owned Russia-1, the host shouted into the camera: 'What are you croaking about? You'll be destroyed along with your America, and no one will even remember your name.' Want all of The Times? Subscribe.

Earnings To Watch: Bio-Techne (TECH) Reports Q2 Results Tomorrow
Earnings To Watch: Bio-Techne (TECH) Reports Q2 Results Tomorrow

Yahoo

time25 minutes ago

  • Yahoo

Earnings To Watch: Bio-Techne (TECH) Reports Q2 Results Tomorrow

Life sciences company Bio-Techne (NASDAQ:TECH) will be reporting results this Wednesday before market open. Here's what investors should know. Bio-Techne met analysts' revenue expectations last quarter, reporting revenues of $316.2 million, up 4.2% year on year. It was a mixed quarter for the company, with an impressive beat of analysts' EPS estimates. Is Bio-Techne a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Bio-Techne's revenue to grow 2.9% year on year to $314.9 million, improving from the 1.6% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.50 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Bio-Techne has missed Wall Street's revenue estimates five times over the last two years. Looking at Bio-Techne's peers in the research tools & consumables segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Mettler-Toledo delivered year-on-year revenue growth of 3.9%, beating analysts' expectations by 2.9%, and Thermo Fisher reported revenues up 3%, topping estimates by 1.6%. Mettler-Toledo traded down 3% following the results while Thermo Fisher was up 11.3%. Read our full analysis of Mettler-Toledo's results here and Thermo Fisher's results here. The euphoria surrounding Trump's November win lit a fire under major indices, but potential tariffs have caused the market to do a 180 in 2025. While some of the research tools & consumables stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.3% on average over the last month. Bio-Techne is up 6.3% during the same time and is heading into earnings with an average analyst price target of $66.50 (compared to the current share price of $54.80). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store